Navigation Links
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Date:10/18/2007

within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risk that the European Commission will not formally approve ATRIPLA for marketing in the European Union prior to the end of the year or at all, and any marketing approval, if granted, may have significant limitations on its use. In addition, Gilead, Bristol-Myers Squibb and Merck may be unable to reach agreement related to the manufacture, commercialization and distribution of ATRIPLA in the European Union in a timely manner or at all. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in the Gilead's Annual Report on Form 10-K for the year ended December 31, 2006 and its Quarterly Reports on Form 10-Q for the first two quarters of 2007, filed with the U.S. Securities and Exchange Commission. All forward- looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements.

Merck Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forw
'/>"/>

SOURCE Bristol-Myers Squibb
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Malvern initiates European user group meetings for chemical imaging
7. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
8. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
9. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
10. Inspire Announces Presentations at Two European Scientific Conferences
11. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today announced ... version of vigabatrin) for the treatment of cocaine and ... based upon, an in-depth review of the results obtained ... use of CPP-109 for the treatment of cocaine addiction ...
... Blue Belt Technologies, Inc., a Pittsburgh based medical device ... for use in orthopaedic and neurosurgery procedures, has closed ... of financing. The round was led by private ... Innovation Works (Pittsburgh) and consisted of both new investments ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 2Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 3Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 4Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 5Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 6Blue Belt Technologies, Inc. Closes Series A Financing 2Blue Belt Technologies, Inc. Closes Series A Financing 3
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... a,new online resource for OTC drugs that have no negative side ... to know that non-toxic drugs are available today as,options to successfully ... are able to achieve relief without the adverse side effects,such as ... so many of us. , ...
... Stephen Joffe, Craig Joffe, and,Alan Buckey today filed an ... Exchange Commission. The group previously filed a 13D,disclosing ... LCAV ), which,operates 77 LasikPlus fixed-site laser vision correction ... Joffe is the founder and former Chairman and CEO ...
... did limit vomiting and results are preliminary, researchers ... Children who were given the steroid dexamethasone after ... they also faced an increased risk of bleeding ... early for safety reasons, a new study shows. ...
... inoperable disease, report says , , TUESDAY, Dec. 9 (HealthDay ... have improved overall survival of patients with advanced breast ... review of 128 clinical trials that included more than ... that use of anthracycline regimens led to a 22 ...
... deadliness of Alzheimer,s, report says , , TUESDAY, Dec. 9 ... fail to record severe dementia as a cause of death ... only points to a lack of knowledge about how dementia ... deadly illness, it suggests that deaths due to Alzheimer,s and ...
... for the Prom a Winner, Features Kelli Pedroia , ... Academy of Dermatology has announced that the Melanoma Foundation of New ... given for "significant contributions to the specialty of dermatology." The award ... in March of 2009. , , ...
Cached Medicine News:Health News:New Resource for No Side Effect Drugs 2Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 2Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 3Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 4Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 5Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 6Health News:Steroid After Tonsillectomy Raises Bleeding Risk 2Health News:Steroid After Tonsillectomy Raises Bleeding Risk 3Health News:Non-Hormonal Therapies Aid Breast Cancer Patients 2Health News:Dementia Often Missed as Cause of Death 2Health News:Dementia Often Missed as Cause of Death 3Health News:Melanoma Foundation of New England Wins Gold Triangle Award From the American Academy of Dermatology 2
Shandon Excelsior ES Tissue Processor continues the Thermo Electron Corporation tradition of offering one of the most advanced, traditional reagent instruments available today....
... the highly concentrated multi-purpose detergent formulated ... with an ultrasonic cleaner. MPD ... and organic material and safe enough ... clean surgical instruments manually or with ...
... grip the patients finger snugly. Wrap the patients ... Steel Finger Trap for an extra secure fit ... create a complete upper extremity traction system when ... Advanced Universal K Table. Stainless Steel Finger Traps ...
... Transmitters slot into ... TeleMon companion monitor, so ... at the patient's side. ... interrupting transmission and storage ...
Medicine Products: